EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States
Abstract
Authors
C Udeze M Jerry K Evans N Li S Jain B Andemariam